secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0000950170-25-076482
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split
--------------------------------------------------------------------------------

- Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.
- Company has 45 days (by July 7, 2025) to submit compliance plan; if accepted, until Nov 18, 2025 to regain compliance.
- Announces 1-for-20 reverse stock split effective May 23, 2025; shares begin trading split-adjusted May 27.
- Files prospectus supplement for up to $3.015M of common stock under ATM with Roth Capital.
- Outstanding shares to reduce from ~13.5M to ~0.7M; no change to ticker APVO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025076482/0000950170-25-076482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025076482/apvo-20250522.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-076482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer